← Back to headlines
Immunic Appoints Erik Lundgren as CEO to Advance Phase 3 MS Trials
Immunic has announced the appointment of Erik Lundgren, a former Genentech executive, as its new Chief Executive Officer, tasked with advancing the company's Phase 3 MS trials.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
